Joel Buxbaum, MD, Scripps Research, La Jolla, CA, talks on improvements in amyloidosis management in recent years, commenting on the progression of options and outcomes in AL amyloidosis. Prof. Buxbaum goes on to discuss the issue of organ responses, specifically cardiac responses and recent advances such as the use of patisiran for the treatment of polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).